Drugs / STX-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06249048 | May 2024 → May 2027 expected | neoplasm | Strand Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06249048 ↗ |
| Modality | Messenger RNA (mRNA) | “self-replicating RNA encoded for IL-12” NCT06249048 ↗ |
| Route | Other | “for intratumoral injection” NCT06249048 ↗ |